146 related articles for article (PubMed ID: 2059436)
1. AZT resistance in isolates of HIV.
Richman DD
Immunodefic Rev; 1991; 2(4):315-8. PubMed ID: 2059436
[TBL] [Abstract][Full Text] [Related]
2. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
[TBL] [Abstract][Full Text] [Related]
3. AZT-related mutation Lys70Arg in reverse transcriptase of human immunodeficiency virus type 1 confers decrease in susceptibility to ddATP in in vitro RT inhibition assay.
Sharma PL; Chatis PA; Dogon AL; Mayers DL; McCutchan FE; Page C; Crumpacker CS
Virology; 1996 Sep; 223(2):365-9. PubMed ID: 8806572
[TBL] [Abstract][Full Text] [Related]
4. [Resistance to azidothymidine in human immunodeficiency virus (HIV) infection].
Karmanov EV; Lukashov VV
Mol Biol (Mosk); 1994; 28(1):7-20. PubMed ID: 7511784
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus.
Richman DD
Am J Med; 1990 May; 88(5B):8S-10S. PubMed ID: 2186629
[TBL] [Abstract][Full Text] [Related]
6. [Resistance of human immunodeficiency virus (HIV) to zidovudine. Genotypic analysis in strains isolated from Chilean patients].
Vial PA; Vial C; Abarca K; Noriega M; Jiménez G; Labarca J; Gasep J; Palacios O; Pérez C; Acuña G
Rev Med Chil; 1998 Jan; 126(1):17-26. PubMed ID: 9629750
[TBL] [Abstract][Full Text] [Related]
7. Loss of zidovudine related mutations in the reverse transscriptase gene of HIV after switching therapy.
Falkensammer B; El Attal R; Müllauer B; Sarcletti M; Parson W; Dierich MP; Stoiber H
Eur J Med Res; 2002 Sep; 7(9):379-86. PubMed ID: 12435615
[TBL] [Abstract][Full Text] [Related]
8. Studies of zidovudine in combination with didanosine and zalcitabine.
Jablonowski H
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
[TBL] [Abstract][Full Text] [Related]
9. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.
Rusconi S; De Pasquale MP; Mainini F; Bulgheroni E; Kurtagic S; Gori A; Violin M; Zanchetta N; Moroni M; Balotta C; Galli M
Antivir Ther; 1996 Dec; 1(4):211-9. PubMed ID: 11324823
[TBL] [Abstract][Full Text] [Related]
10. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.
Winters MA; Coolley KL; Girard YA; Levee DJ; Hamdan H; Shafer RW; Katzenstein DA; Merigan TC
J Clin Invest; 1998 Nov; 102(10):1769-75. PubMed ID: 9819361
[TBL] [Abstract][Full Text] [Related]
11. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
Jeeninga RE; Keulen W; Boucher C; Sanders RW; Berkhout B
Virology; 2001 May; 283(2):294-305. PubMed ID: 11336554
[TBL] [Abstract][Full Text] [Related]
12. Selection of zidovudine resistance mutations and escape of human immunodeficiency virus type 1 from antiretroviral pressure in stavudine-treated pediatric patients.
Maxeiner HG; Keulen W; Schuurman R; Bijen M; de Graaf L; van Wijk A; Back N; Kline MW; Boucher CA; Nijhuis M
J Infect Dis; 2002 Apr; 185(8):1070-6. PubMed ID: 11930317
[TBL] [Abstract][Full Text] [Related]
13. Intermittent selection pressure with zidovudine plus zalcitabine treatment reduces the emergence in vivo of zidovudine resistance HIV mutations.
Izopet J; Sailler L; Sandres K; Pasquier C; Bonnet E; Aquilina C; Puel J; Massip P; Marchou B
J Med Virol; 1999 Feb; 57(2):163-8. PubMed ID: 9892402
[TBL] [Abstract][Full Text] [Related]
14. Additional mutations detected in sequential HIV-1 isolates from ZDV-treated patients.
Magierowska-Jung M; Agut H; Katlama C; Autran B; Huraux JM
J Med Virol; 1997 Jan; 51(1):48-55. PubMed ID: 8986949
[TBL] [Abstract][Full Text] [Related]
15. Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine.
Atkinson B; Isaacson J; Knowles M; Mazabel E; Patick AK
J Infect Dis; 2000 Aug; 182(2):420-7. PubMed ID: 10915071
[TBL] [Abstract][Full Text] [Related]
16. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
Larder BA; Darby G; Richman DD
Science; 1989 Mar; 243(4899):1731-4. PubMed ID: 2467383
[TBL] [Abstract][Full Text] [Related]
17. Zidovudine and lamivudine: results of phase III studies.
Staszewski S
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
[TBL] [Abstract][Full Text] [Related]
18. Roaches of inner space.
Gilden D
GMHC Treat Issues; 1995 Oct; 9(10):1, 14-6. PubMed ID: 11362912
[TBL] [Abstract][Full Text] [Related]
19. Synergistic inhibition of AZT-resistant HIV by AZT combined with poly(I):poly(C12U), without synergistic toxicity to bone marrow progenitor cell elements.
Gillespie D; Hubbell HR; Carter WA; Midgette P; Elsasser W; Mullaney R; Strayer DR
In Vivo; 1994; 8(3):375-81. PubMed ID: 7803722
[TBL] [Abstract][Full Text] [Related]
20. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
